Sanofi India Ltd (NSE:SANOFI) Q4 FY23 Earnings Concall dated May. 11, 2023.
Corporate Participants:
Radhika Kartik Shah — Company Secretary and Compliance Officer
Rodolfo Hrosz — Managing Director
Vaibhav Karandikar — Chief Financial Officer
Analysts:
Abdulkader Puranwala — ICICI Securities — Analyst
Saurabh Savla — Multi-Act — Analyst
Himanshu Upadhyay — o3 Capital — Analyst
Gagan Thareja — ASK Investment — Analyst
Presentation:
Operator
Over to Sanofi management team.
Radhika Kartik Shah — Company Secretary and Compliance Officer
Thank you. Good morning, everyone, and a very warm welcome to the Investor Call of Sanofi India Limited. My name is Radhika Shah, and I’m the Company Secretary of Sanofi India Limited. I have with me; Mr. Rodolfo Hrosz, Managing Director and Mr. Vaibhav Karandikar, Whole-Time Director and CFO. Good morning.
Rodolfo Hrosz — Managing Director
Hello. Good morning, everyone, and welcome.
Vaibhav Karandikar — Chief Financial Officer
Good morning, everyone.
Radhika Kartik Shah — Company Secretary and Compliance Officer
Okay. Before we begin this investor call, there are two important announcements. Firstly, [Operator Instructions]. Secondly, please also note our standard disclaimer, there are certain statements, which may be forward-looking in the presentation as well as the comments that the management makes. The actual results may be affected by many factors that may be different from what is envisaged in terms of future performance and outlook that is being discussed today.
Moving on to the agenda of this call. In today’s investor call, we will be talking about the performance of the company for Q1 2023, and also the proposed demerger, which we have — which the Board of Directors have approved yesterday and it was announced yesterday. All of you would have seen the press release and the news articles.
The management will make a presentation covering the performance as well as the proposed demerger-related aspects. And, thereafter, we will proceed to Q&A. We expect the Q&A to end by 12:00 p.m. sharp. All investors are requested to keep their questions brief and kindly avoid repetition.
I now hand over to Rodolfo to take us through the presentation.
Rodolfo Hrosz — Managing Director
Thank you, Radhika, and once again, thank you for joining a very exciting news to share today. So I’m very, very happy to be here. So the agenda today entails four points. We’re going to start with the Sanofi Limited overview. We’re going to go through keys for change. We’ll share a little bit on our transaction overview. And then there is an appendix that we’ll go to you when the presentation is upload.
Starting with Sanofi Limited, a brief overview for those that aren’t totally familiar with the business, we have a long history in the country, 67 years of presence in India, a top four multinational company in the pharmaceutical industry. Our revenues of INR26.2 billion in 2022, top five — are in the top 300 of total market, total pharmaceutical market in India. We export to 28-plus countries around the world, developing and developed countries. We have one strong GMP compliant manufacturing site in Goa, five billion tablets produced from that facility, 12 Indian CMO, Contract Manufacturing Organizations that work with us for the Indian market and for exports as well.
We cater to 3,000 distributors and 100,000 pharmacies with very strong activity in CSR and ESG. In CSR, we have various long-standing health programs for underserved communities and where we have reached INR2.4 crore total beneficiary so forth. Environment, as you may have seen in our new annual report, we have disclosed more — some interesting new information.
We are total — we plan to be totally 100% renewable energy by 2030, net zero by 2045, and we continue to seek a circular approach to limit our environment impacting our activity, very robust governance on that point, but fully compliant with multiple areas of the internal and external audits to our operations. So that gives you a brief overview of the company.
In the next slide we’ll show you a little bit about leading brands who are well-positioned in the biggest segment of the pharmaceutical industry in India with very strong established leading brands from insulins with Lantus, Toujeo and Apidra with a portfolio in oral diabetes with Amaryl, amongst other brands, Clexane for cardio, Frisium in the neuro segment, Allegra in the allergy segment, Depakote in the physical wellness, Combiflam in pain management; and Aubagio also in allergy, strong portfolio with very robust brands very well established.
Next slide, I’ll show you a little bit of our returns in the last few years. I asked Vaibhav at to take us through that slide.
Vaibhav Karandikar — Chief Financial Officer
Thank you, Rodolfo. As you can see on the slide, we have created a long-term shareholder value. If you look at the chart from 2010 to 2023 today, market cap plus dividend put together, we have delivered 5 times in terms of total returns for our shareholders, which translates into a compounded growth rate of 12.2% over this 10-year period.
I think one point also that we want to stress and which we have mentioned during the last call as well, is the dividend payout ratios. And we talked about India for India strategy in Q3 2022, and we also shared that with you during the last investor call, largely, the strategy focused on global and local innovation and partnerships which is essentially meaning an organic path to growth for Sanofi, which we are pursuing.
And therefore, we said that, we would be able to maintain our payout ratio, which, as you can see, are gradually increasing and the last payout ratio was 85% this translates into a dividend yield of almost 3%, 3.5% on the — for our shareholders. And that’s something which is a key factor under India for India, which we wanted to share with you. And this is something that one needs to keep in mind as we move along in terms of our payout ratios going forward.
Next slide, please. Yeah. And the important thing is now on — while we have delivered long-term shareholder value, I wanted to talk about a little bit on what we have done under India for India. To refresh the memories, we launched India for India in Q3 of 2022. India for India essentially focuses on growth pillars, diabetes, CFC, innovation, new ways in terms of go-to-market and partnerships. And while we are working on these five pillars, it’s important to note that, there are strong early signs of success in the last two quarters.
If you look at Q4 of 2022 and we shared these numbers with you, we showed a growth of 22% on our profit before tax. The operating efficiencies, which were brought in by India for India, they kicked in Q4 2022. Q1 2023, the results which were published yesterday, I think it’s an important point to note that this was one of the best quarters for Sanofi India in terms of profitability. If you look at the last 17, 18, 20 quarters, I think this was the highest profits that Sanofi India made during the quarter. Again, it was — look, we kind of are moving on the India for India direction very strongly, as you can see.
The comparable sales growth versus the previous year was at 9%. And importantly, the operating profit growth is at 21% during Q1 2023. One more point, which one needs to note is if you look at the immediately preceding quarter, the operating profit growth between Q1 2023 and Q4 2022, the operating profit growth is at 40%, while India for India strategy is clearly showing early success, we need to accelerate more. There is strong acceleration needed on all in the five growth pillars because we want to reach more and more patients in India, and that’s an important milestone for us as we deliver on our India for India growth platform.
Rodolfo Hrosz — Managing Director
Thank you, Vaibhav. And in fact, I think good results we can stay there for a minute. Good results, even if you consider that these were the quarters in which we implemented a new structure that is catering to the new India for India plant, right? So a significant shift in the organization that has been absorbed within these two quarters, then nevertheless, the quarters are good. So it’s even more interesting from that perspective. It does signal that focus on key categories and fewer initiatives pays out and because if you look at the essence of what has changed in the last two quarters, it is really more focused, right? We came from eight business units down to three business units with more focus on more resources in fewer bets or we believe we are well positioned to succeed and have the right to win in the bets that we’re focusing on.
So focus has been at. Innovation, we started to work on, but innovation really impacts the business down the road. The innovation process is relatively longer. So it takes more time for innovation to hit the market from the moment you start to work on it in the pharmaceutical industry. So, it will impact us positively in years to come, but not — hasn’t been the case in Q4 and Q1 so far. So it’s really focused. And focus, focus is something that we can elevate even more, right?
In the next slide, we can — as we go through the exercise of focusing on these two businesses and driving the performance of these two businesses. We realize more and more, clear that what we offer, what we — what enables growth, the market dynamics, the keys to innovation and the external environment challenges are different for General Medicines, for the Pharma Business. We sell products with therapeutic benefits. It’s about scientific HPE engagement and HPE health care professionals. It’s the dynamics involved the SCRIPT PRESCRIPTION. It’s a prescription-driven business.
It is about communicating on disease and therapy awareness. R&D and clinical trials are critical. Patients and institutions are the payers. And there is a need for a strong regulatory path for innovation. If you go to the consumer healthcare side of the segment of the business, we offer brands to fulfill consumer needs. It is critical that we have strong consumer marketing, modern trade visibilities is very important factor of success.
We talk about health care and influence. It speeds to market, its critical in innovation. And consumers are the ones who pay. And in terms of external challenge, the external challenge is regulation for the whole category of OTC.
So, very distinct needs that require distinct and different approaches, so we think that in the next slide, we can maximize the Sanofi India’s potential and our current India — for India plants potential by giving each of these segments, specific capabilities, removing unnecessary and intertwining processes that today exist and fully aligning these businesses with the respective global structures.
And this has led us to what you saw in the next slide. What you saw already last yesterday in the press release when we announced that the Board of Sanofi India Limited approved the decision to de-merge the consumer health care business from the Pharma business. So yes, this is subject to multiple approvals, including shareholders’ approval. But there has been approved the aspect by the Board and that you’ve seen that communication.
Now when we talk about that — what is the context in which this decision is being made? If you look at this market even from a global perspective, a very broad perspective, right? So you see that pharma companies have taken a similar path in dedicating organizations for their consumer health care portfolio. It is the case with Haleon, which time ago announced a spin-out. It is the case of Johnson with Kenvue, an IPO for the Consumer Healthcare portfolio. And it’s also the case with some local companies in the recent past.
Aside from that, from pharma companies dedicating structures for your consumer health care portfolio, we also see fast-moving consumer goods, stepping into the consumer health care portfolio Heineken, Procter & Gamble, Unilever and Nestle have all taken steps to get into that segment and then changing therefore, the dynamics of the segment. It is natural. It is a very attractive market.
Today estimated $150 billion projected to be over $200 billion by 2027 globally with multiple factors that make us believe that this growth is really very sustainable for a very long time. We have a heightened and increased consumer focus on health and wellness, increased budget pressure on health care systems around the world, driving the adoption of self-care policies, which relieve payers from some of the burden of the health care system, aging population is another important factor, we — as people grow older and more and more of a need to cater for their health and do that with a proactive and preventive self-care approach.
It is estimated by the WHO that the 60-plus population will double by 2050 in the world. So this is a really big impact that is going to shape the landscape. There is an expanding middle class with a high-growth emerging markets such as our market in India. And there is a very fast-growing digital ecosystem that provides consumers and patients’ new opportunities to interact, learn and they make decisions on self-care. So, all these factors together, paying for this very positive perspective on Consumer Health care, which has led companies to take significant action in adjustment in their strategies to cater to this opportunity.
In the next slide, we see that not only competitors have done that, as I saw — I shared with you in the previous slide, but also Sanofi has been going down these road offs, right? Since January 2020, Sanofi globally deployed project2D [Phonetic] — whereby the company decided to give autonomy and independency for its consumer health care business within the Sanofi Group. So a stand-alone consumer health care business — global business unit has been the making since January 2020.
At this point, most of the countries around the world are already operating with independency and autonomy within the Sanofi Group. In fact, since the beginning of that project implementation, the velocity of growth and the speed in which that business grew globally quadrupled, as you can see in the chart. When we talk about India, it is a great opportunity for the consumer Sanofi, consumer health care business in India to tag on to that successful proven trajectory that the group has deployed already in multiple markets in most markets to this date.
India is a very important key market for consumer health care in general. It is number six. It ranks for consumer health care globally. For Sanofi it ranks already 10 even if you see already a gap there, even 10 is already very relevant. So it will be a key market for the — for the global business unit of Consumer Healthcare of Sanofi. In its journey to continue to accelerate and achieve growth at least twice as as the category globally, which is the intention and ambition of this business globally. And India is going to play a major significant role in that context.
In the next slide, I show you that at the end, what we were creating here, — we’re creating a situation where we give the Sanofi India consumer health care business, the best of two worlds right, on the one hand, access to the expertise of the global business unit in marketing, innovation, market shaping and at the same time, giving this business the independence and agility and autonomy that they need to pursue its own growth drivers in the Indian market with resources that are fit for purpose that addresses those drivers that I mentioned earlier in the previous line,
At the same time, GenMed is able then to focus the general medicines for the pharma market, the business is able to focus on its growth drivers. which has been outlined very clearly already — India for India. So that is the benefit for the two sides of the organization, right?
So next give you a transaction review, I ask Vaibhav to come back and give us a transaction review.
Vaibhav Karandikar — Chief Financial Officer
You would have seen yesterday in the stock exchange announcement and also the press release that we talked about the transaction, but to kind of summarize it, what would it be? We have the current structure today that Sanofi holds 60.4% in the listed entity, Sanofi India Limited and public shareholding is 39.6%.
In the proposed structure, we will have two entities, two listed entities. The first entity Sanofi India Limited, which will essentially house the General Medicines business. And the second entity is Sanofi Consumer Healthcare, which will house the CHC business of the company. Shareholders of Sanofi India Limited will get one share for every one share of what the hold in Sanofi India Limited. So they’ll get one share of Sanofi Consumer Healthcare for every one share of Sanofi India Limited. So Consumer Health care is the demerged entity, which is Sanofi Consumer Healthcare is supposed to be listed on both the BSE and NSE. The expected closure of the transaction is mid-2024. Of course, it is subject to shareholder and regulatory approvals. And Sanofi will continue to hold 60.4% in both the entities. So this is the way the transaction will move between the current and the proposed structure.
Okay. Can we go to the next slide, please. This is an important chart in terms of understanding the two businesses a little bit. Key factor to note is that both the businesses are strong, stable businesses with resilient and durable cash flows. And that’s because both the businesses are having top-quality brands well entrenched in their respective categories and therapies.
If you look at general medicines, for example, you have brands like Lantus, Toujeo Amaryll, Clexane but beyond these brands, we have other products. We have products like Cetapin. We have products like Cardace H products like Cardace, which are not listed here. but essentially a strong portfolio of brands in general medicines, which will enable us to continue with the stable and the resilient cash flows, which is one of the most important factors for Sanofi in India, today.
If you look at Sanofi consumer healthcare also, super brands like Allegra, combiflam, well-known names, we have dexona, Avil again, strong brands and extremely well entrenched in their respective categories. A couple of other points to note in terms of financials. Consumer business of Sanofi India is almost 28% of the total business of Sanofi India. Turnover annually would be in the range of INR700 crores.
Important point just to highlight, the manufacturing unit, which is the Goa manufacturing unit, will be remaining with the General Medicines business because it is predominantly catering to the pharma side of the business. And CHC, just like today, we’ll focus more on their local manufacturing to toll manufacturing and CMO organization. Back to you, Rodolfo.
Rodolfo Hrosz — Managing Director
Thank you, Vaibhav. Yes. CCT supply some from Goa, continue to do Goa becomes — eventually becomes core manufacturer for CC too. Now if you then ask me, what is it then that Gen Med is going to focus on and CT is going to focus on, right? So Gen Med, the General Medicines portion of the business, pharma business continues to focus on the growth drivers that we identified in India for India, which are strengthening the strategic therapeutic areas. So we want to further focus resources on the therapeutic areas of choice where we can attain leadership
Elevate disease awareness and efforts on these core categories further improve scientific support and ECP engagement in these categories with scientific content developed of relevance for the inland market. Accelerated innovation is our second pillar. And in there, we plan to bring opportunities of innovation from both global portfolio and local opportunities that exist we hit our portfolio.
We want to further localize manufacturing for gross margin expansion, improving supply reliability and speed-to-market and strengthen the regulatory pathway and other capabilities to support our innovation plan.
The third pillar for General Medicines in India is to continue to evolve its growth, its go-to-market strategy, where we intend to improve patient and customer centricity, continue to accelerate and accelerate even more our digital transformation and evaluate strategic partnerships that allow us to expand reach in competitive and resources and therapeutic areas.
As Vaibhav said, and as I mentioned before, we are committed to a healthier India, and we want to take our portfolio to more Indians, to many more millions of Indians that we need to find ways to do. So that is what the General Medicines business is focused on. For the CT side, for the CT segment, we’re positioning the business through actually create a fast moving consumer healthcare, right? And there, the drivers are different. So first, there is an enhancement of the portfolio innovation through line extensions and potentially in the future addition of other global brands that are not in the portfolio today, increase market penetration, shape the modern OTC regulation.
India’s OTC regulation is not modern yet, it needs to be modernizing as it does, it allows a tremendous expansion for these categories. Build a consumer-centric mindset is the second pillar. There, we want to deepen our affinity with consumers with a lot more research, a lot more consumer understanding, enabling that we build a strong marketing — do we deploy a strong marketing effort to build awareness and accelerating the building of log brands in India.
We have some log brands already. Some of our brands are still already loved. We want to continue to build them and build them even bigger, right? We want to enhance our presence in modern trade as it is already important for this business and is going to become growingly more important going forward.
Third pillar for the CC business is to become a best-in-class digital organization with strong e-commerce capabilities. There’s three elements there. One is specifically to immediately step up e-commerce. Second, to build a world-class digital marketing capability for those brands and essentially to fully leverage the global CC business unit, data and digital edge. So the global structure of Sanofi for Consumer Healthcare is fairly well advanced and best-in-class in terms of that its digital capability. So it’s a straight benefit to this portfolio as we go forward.
In our internal plans, we are still evaluating other opportunities that are not in our base plans but are going to be evaluated. The potential for inorganic growth exists and is going to be looked at. We continuously look for those opportunities and it would be the case in the Consumer Healthcare segment as well and direct-to-consumer opportunities another one that can be explored down the road, right? So those are the different priorities for GenMed and for consumer healthcare.
If we go to the next slide, I’ll try to summarize what are the key benefits from this merger, right? So first and foremost, we — the plan takes us through a proven path to unlock significant value creation for shareholders, right? And we’re not the first doing it. We’re not the first company and inside Sanofi were not the first market. So this is relatively a proven path to a lot growth. And growth comes from two sources here, the operation in itself, as we’ve been talking about during this presentation all along and even from a valuation perspective.
As we believe that our CC business is valued today at multiples that are more applicable to pharma. And once you separate the businesses, more clarity will be given for this business to be properly evaluated and multiples can be properly adjusted, which we believe will also unlock value for our shareholders.
GenMed will — as a consequence of this separation, GenMed will be able to restlessly focus on its key and growth drivers, focusing on its key categories global and local innovation, go-to-market and reach expansion, which are big tasks that need to be undertaken by this organization.
Consumer Healthcare takes off as a fast-moving Consumer Healthcare organization with proper capabilities, analysts back to my point from other, who have — analysts and investors who have more ability to evaluate these businesses with more clarity with deeper understanding of the two highly focused and separate businesses. And most important for Sanofi altogether, it gives us a better chance to be able to improve the lives of millions of patients in India, which is ultimately where it all begins. India for India began with this ten top demand. It is continues to be what we want to do. And to do that, we need to grow. To grow we need to find the right strategy. And we’re convinced this is the right strategy to facilitate our growth.
So I pause here and over to you, Radhika.
Radhika Kartik Shah — Company Secretary and Compliance Officer
Thank you. Thank you, Rodolfo. So now we move on to the Q&A session. In this session, I’d just like to remind you once again that we will be answering questions within the boundaries of our internal policies as well as SEBI regulations, as required by law [Technical Issues] policies, we will restrict our responses to clarify on matters, which are already available in public domain and through our annual reports and financial results, which we have made public.
There are granular aspects of certain aspects of the business like product-wise sales, therapy, area-wise sales and margins and profitability, which we consider confidential, hence we will not be able to comment on these topics. We also do not provide any earnings guidance. And hence, we will not be able to respond to queries on future businesses and margins and profitability and capex, etc. You will please raise your queries accordingly.
Further, we had mentioned on our registration link that we will be taking questions from you in sequence of your registration, in case of multiple registrations from the same participant, we will take questions from the first registered participant and give others the opportunity at the end of this session. In the interest of time and for giving equal opportunity to all the participants, please keep the number of questions limited to one or two.
Thank you. I hand over to the team for the Q&A session.
Questions and Answers:
Operator
Thank you very much, ma’am. Ladies and gentlemen, we will now begin the question-and-answer session. [Operator Instructions] We take the first question from Himanshu Upadhyay from O3 Capital. Please go ahead. Mr. Upadhyay, could you please unmute your audio with proceed with your question. Your microphone is muted, sir. Please go ahead with your question. There seems to be no response from Mr. Himanshu’s Connection. We will move to our next question. That’s from the line of Abdulkader Puranwala from ICICI Securities. May I request you to please unmute your audio and go ahead with your question?
Abdulkader Puranwala — ICICI Securities — Analyst
Yes, hi. Thank you for the opportunity. Sir, first question with respect to your Q1 results. So, first of all, congratulations on the good set of numbers. So if we have to break up this 4% growth within the two portfolio of General Medicines and the consumer business. If you could provide some color as to which is the one which has driven growth and historically, is that the case been in CY ’22 as well?
Vaibhav Karandikar — Chief Financial Officer
So I think we don’t disclose by the results by brand, right? Yes. But we can tell you that we currently operate with three business units in it, right? So from — we came from — the three have performed very well in Q1, delivering growth and delivering within the expectations for each one of them. So, it was a fairly strong quarter across the more for the portfolio with no major distinction. So if you’re asking, is it more on the pharma side? No, it’s pretty well distributed across the portfolio.
Abdulkader Puranwala — ICICI Securities — Analyst
Got it. And my second question is with regards to the kind of transactions, what we would see between the General Medicine business and the consumer arm post getting demerge. So would you also have a split fee force or manufacturing something that you called out? But then apart from that, what would be the kind of transactions or would be still link between both these entities?
Rodolfo Hrosz — Managing Director
Do you want to take this one?
Vaibhav Karandikar — Chief Financial Officer
Sure. So the two entities would be largely separate. There would be no — I think your question is, will there be common services or common transactions between Sanofi India Limited and Sanofi Consumer Healthcare Limited. No, the answer is that the sales force, marketing teams, etc., including the support functions would be largely separate and catering to consumer health care separately. There may be a transition period arrangements. But on a long-term basis, it would be to separate businesses. What would continue like Rodolfo pointed out was the — is that Goa will continue to manufacture certain products for the consumer health care business under the contract manufacturing arrangement. That would be a more long-term kind of — which would be a more sustainable arrangement between the two entities. But other than these two, there will be no entanglements.
Abdulkader Puranwala — ICICI Securities — Analyst
Sure, sir. And just final, if I may. So, on the margin front, I mean, as highlighted the Q1 margins were a record of 31% on the EBITDA front. So, if you could like to call out what were the drivers for this margin? And going ahead, what is the kind of trajectory we should see into the EBITDA margins?
Rodolfo Hrosz — Managing Director
Going forward, I don’t think we’ll be able to answer it. But on the Q1, I will start and then maybe you can comment it. So we have two major components. One is the growth of the business. And another one is India for which it brings efficiencies into the operation, right? So we rationalized significantly our operation already at the beginning of delivery. That contributes also on top of sales performance. You may want to complement on that?
Vaibhav Karandikar — Chief Financial Officer
Yes. So just to add to what Rodolfo said, so the growth in both the domestic and the export segment is quite healthy in this quarter. And when I look at the domestic segments, I’m talking about the retail business because there is still some element of the divested portfolio that is there. But essentially, the growth is quite healthy in both the segments and that contributes to this. And the operating expenses, like Rodolfo was mentioning, is the India for India strategy implementation, which started in 2022. I think we continue on that journey, and that helps us to also have better efficiencies in our operating structure.
Abdulkader Puranwala — ICICI Securities — Analyst
Got it. Thank you. I’ll turn back the queue.
Radhika Kartik Shah — Company Secretary and Compliance Officer
Thank you.
Operator
Thank you. We’ll take our next question from Saurabh Savla from Multi-Act. Request you to please go ahead with your question, if you could mute a mic from your device and go ahead.
Saurabh Savla — Multi-Act — Analyst
Yes. Am I audible?
Radhika Kartik Shah — Company Secretary and Compliance Officer
Yes, Saurabh.
Rodolfo Hrosz — Managing Director
Yes.
Saurabh Savla — Multi-Act — Analyst
Yes. Thank you for the opportunity. I had a question related to the Consumer Healthcare business. If you could give us what has been the growth rate in that particular division for the last five years like from 2019, which is a pre-COVID period till last calendar year?
Rodolfo Hrosz — Managing Director
I think we’ll be able to give that after we…
Vaibhav Karandikar — Chief Financial Officer
I can give a — between 2018 onwards, roughly, it’s in the range of 8%, 8.5%.
Saurabh Savla — Multi-Act — Analyst
Okay. And what could be the broad split between the volume and pricing growth of this 8%, 8.5%?
Vaibhav Karandikar — Chief Financial Officer
I don’t have precise information on price volume for the entire five-year period. But since Consumer Healthcare is largely out of price control, there would be a reasonably good portion of price growth embedded into that.
Saurabh Savla — Multi-Act — Analyst
Okay. And the last question would be, if you could just ballpark or a guidance — not the guidance, but how would be the margin profile different from the consolidated entity? Thanks.
Vaibhav Karandikar — Chief Financial Officer
I think if you look at our operating profit margins today on the consolidated basis, we are in the range of 25%, 26%. Consumer Healthcare has a better margin profile. So the blended mark — compared to the blended margin, the consumer health care margins would be at least 8% to 10% higher.
Saurabh Savla — Multi-Act — Analyst
Okay. Yes. Thank you.
Rodolfo Hrosz — Managing Director
Thank you, Saurabh for the question. Imagine we have it listed and we can then have all the visibility on all the questions that you addressed. Thank you for your question.
Operator
Our next question is from Himanshu Upadhyay from o3 Capital. Request you please unmute your mic and go ahead with your question.
Himanshu Upadhyay — o3 Capital — Analyst
Thank you for having me. I just have a few questions. So diabetes care is a main focus area for us, and there is a huge unmet demand and diagnosis of it in the country. What are the incremental things that we are doing to grow the opportunity and better service the market? And what resources are we investing?
Rodolfo Hrosz — Managing Director
All right. Very good point. Yes, it is really a very big opportunity still. Although, diabetes is our biggest business in India. And although despite the fact that we’re one of the leading companies in diabetes, the opportunity in diabetes is very large, as you said. We estimate that 140 million people our diabetic or pre-diabetic or at risk of being line, one in seven diabetic patients in the world here from India. So it’s a very significant prevalence.
And despite the high prevalence the percentage of diagnosis is relatively low from the people that are diagnosed, the percentage of treatment — people that are under treatment is also not sufficiently good yet. And even for those that are under treatment, there is a step down in towards treated and control, right? So there is a huge funnel of opportunities for diabetes in industry to fully agree with you. And that’s why it is one of our focal points in our strategy to continue to grow and develop in that category.
Now what are we doing? I think your question was on that point, right? So in India for India, we — as we elected that as one of our core priorities, core pillars. We have dramatically increased the sales force in the product portfolio. So we now have close to — closer to double the resources that are — that were on the field to cater to this agent, health care professionals that treat and deal with the population that is diabetic or even the pre-diabetic population. So that was one thing that we did.
Second thing that we did in order to advance more with the diabetics opportunity, we also really look into our positioning of our brands and dedicate specific brands to specific needs with more clarity thus facilitating the use of that portfolio by HCPs in their important mission to help the patient group of diabetes. More we have deployed initiatives to bring new products to the market, right? So of course, we can’t speak, as Radhika mentioned in the beginning of the Q&A, exactly about details of our pipeline. But there is one piece of — two pieces of public news that you can connect to this conversation.
One is you see on the — in the news that Soliqua one of core — these products globally has been just recently approved by the authorities for launch in India. So you can see the pipeline there in a way that will allow us to be even more present in important segments of the therapies for diabetes where we are not super strong today with a very breakthrough formulation and proposition to ACPs and patients — with very positive impact for patients ultimately.
And even if you look globally, you’ve seen also the news that Sanofi just recently acquired a company called Provention Bio who has developed a product called TZIELD that is a complete breakthrough innovation that delays the onset of the diabetes Type-1 by a number of years, which is a tremendous impact, tremendous positive impact for patients of the diabetes Type-1. And so all these are in the pipeline. And of course, we continue to explore more opportunities to enhance the portfolio of diabetes and with that cater to those opportunities that you rightly mentioned in your question.
Himanshu Upadhyay — o3 Capital — Analyst
Thank you so much for the detailed answer. My other question is that in our non-report statement, we have spoken about product innovation, both globally and locally developed. Can that be elaborated? And how are we doing that? How are we going about it?
Vaibhav Karandikar — Chief Financial Officer
Yes, we have global brands that aren’t present in the portfolio in India yet. Right? One case I just mentioned to you that Soliqua has just been approved by the authorities for launch in. Like that, there are more brands that are in the portfolio of Sanofi. They haven’t been introducing yet. So we plan to explore that generally, right?
And then secondly, India is the pharmacy of the world, right? So in essence, everything is producing a there is a very good quality of the medicines produced in India and a very wide availability of CMOs and manufacturing companies that can develop and produce for the needs that Sanofi has in India too. So that’s how we intend to take Telco [Indecipherable] global and local initiatives. So global, there’s more brands that can come to our portfolio in India from the global Sanofi portfolio. And locally, there is an opportunity to bring line extensions and adjacent innovation to our existing portfolio by working with the local manufacturers in India even with our own site in Goa, which is an extremely capable site, by the way. I hope.
Himanshu Upadhyay — o3 Capital — Analyst
I have one last question. Another thing that is mentioned in the annual report is that our company is now structured to be more customer-centric and has a hybrid model. What does that mean exactly? Well, that’s a good question again. Thank you. I think what we said is that we need to continue to — our effort to become more customer-centric and patient-centric as an organization, right? So that is to reflect the fact that we come from an organization that was organized around the product and from the product reach the market, right? So we want to shift that angle and organize ourselves more from a patient perspective and a health care professional perspective, and then connect our portfolio to it. Some steps have been taken already. More can be taken down the road. In the beginning of India-for-India was we deployed India-for-India. We already took an important step when we created categories and in business units that cater more fully to healthcare professionals that deal with a certain disease. Take diabetes, for instance, in the past, we had two business units with different products catering to the health care professionals that deal with diabetes. Today it’s part of one larger portfolio with one central line of thinking, bringing all these resources and all these possibilities and alternatives to that particular health care professional. That’s what we mean by becoming more health care professional — more customer-centric in one way. Another aspect is we have developed and launched a trade organization in where we now have got a team of people that take our products and engage with our trade partners with an overall view of the whole portfolio. In the past, again, we were engaging with our customers on a brand-by-brand basis. Now we are now able — we’re building the capability of engaging with our trade customers on a portfolio basis — on a full portfolio basis, which unlocks a lot of opportunities for the — for our trade partners and for ourselves, makes us more customer-centric in that sense as well. And so that’s an evolution. But we have taken these steps. Hybrid, to your point on hybrid, with COVID, we developed the capability of engaging with our customers and health care professionals remotely, right? Post-COVID, there is a decline in the adherence of health care professionals to that mode of contact. But we have learned a lot in that process and we believe we can build a route to reach HCPs around India and customers in a digital way that is going to be attractive to them and going to be competitive. This is still in the making. It’s something that we develop more based on what we learned and developed during the COVID pandemic. Thank you. Thank you so much. I don’t have any further questions.
Operator
Thank you. Our next question is from the line of Punit Pujara from Helios Capital. Mr. Punit Pujara, could you please go ahead with your question? You may unmute your audio and proceed with your question.
There seems to be no response from this line. In the meanwhile, we will move to our next question, that’s from the line of Parag Thakkar from Anvil Wealth. Mr. Thakkar, please unmute your microphone and go ahead with your question. Mr. Parag Thakkar, please unmute your microphone or accept the unmute prompt on your screen and go ahead with your question.
There’s no response from Mr. Parag Thakkar’s connection. We will therefore move to our next participant that’s from the line of Nalin Shah from NBS Brokerage. Mr. Nalin Shah, please go ahead with your question, sir.
There’s no response, we’ll check the connection. In the meanwhile, we’ll take our next question, that’s from Mr. Pritesh Chheda from Lucky Investment Managers. Please go ahead with your question.
There is no response from this line. [Operator Instructions] We now request Mr. Vishal Manchanda from Systematix Group to please unmute your audio and ask your question.
Rodolfo Hrosz — Managing Director
Are we sure that we don’t have a system issue?
Vaibhav Karandikar — Chief Financial Officer
Yes. because this is the fourth one, we have a problem probably.
Radhika Kartik Shah — Company Secretary and Compliance Officer
Do you foresee any system problem at your end or at participants’ end?
Operator
Well, it looks like the participant has not allowed the microphone to access, and that’s the reason why we are unable to hear. We request Mr. Gagan Thareja from ASK Investment to please unmute your audio and go ahead with your questions.
Gagan Thareja — ASK Investment — Analyst
Yeah. Am I audible?
Rodolfo Hrosz — Managing Director
We’re very glad to hear you because now we know it’s not a systems issue.
Gagan Thareja — ASK Investment — Analyst
Thank you. Sir, my first question is whether the impact of the revised pricing on Lantus, Cardace and Frisium, has fully been seen in the first quarter? Or is it yet to be seen in the second quarter?
Rodolfo Hrosz — Managing Director
No, it hasn’t been seen in the quarter. I mean, mostly it is going to be seen from quarter two onwards. The impact is mostly the biggest impact is on Lantus, and that is from April onwards. So the entire result of Q1 does not take into account the NLEM price impact.
Gagan Thareja — ASK Investment — Analyst
Right. And going back to your previous conference call comments that you’ll be able to protect gross margins vis-a-vis the transfer pricing. I understand gross margins will be protected but because the pricing will flow down to the EBITDA level, you would have some fixed costs also there ideally should be some impact at the operating level because of the substantial correction in Lantus prices, from Q2 onwards. Is that a correct surmise?
Vaibhav Karandikar — Chief Financial Officer
No, Gagan, I think in the last investor call also, we made the statement that the operating profit percentage to sales will remain constant. So it’s not just gross margins. The operating profit percentage will remain constant. So we will adjust the purchase prices accordingly. There might be a transitionary impact considering inventory levels, etc. But again, to reinforce the operating profit percentage will be constant.
Gagan Thareja — ASK Investment — Analyst
Okay. Which brings me to my next question, which is that you — when you bifurcated the margins between your CHC and general medicines, you took last year’s 25%, 26% is the base, whereas the Q1 margins are already 31%, should we then take 31% as a base and then understand the margin profile of both the companies?
Vaibhav Karandikar — Chief Financial Officer
So you are kind of going forward looking there. The reason I gave you, as an example, 8% to 10% was to give you a sense of the blended margins. I would not like to go and say that x percentage quarterly margins are always going to be sustainable that will be a forward-looking statement. But it’s more to give you an indication that the CFC margins will always be 8% to 10% higher than the blended margins.
Gagan Thareja — ASK Investment — Analyst
But you’ve indicated that there’s a certain element of business restructuring, which is put in cost efficiency. So can you enumerate the cost efficiencies from the business restructuring so that it’s possible for us to understand what’s sustainable in terms of margins?
Vaibhav Karandikar — Chief Financial Officer
So maybe I’ll answer that and then if required, Rodolfo can complement. I think — there is an element of restructuring that Rodolfo talked about and which led to operational efficiencies. And while there is this restructuring that happened, there’s also a transition period for the teams to settle down and therefore, to start all the activities around promotion, patient support programs, etc. So while there is a portion which is permanent and which is going to be continuing in nature, there’s also a portion in that quarter one performance, where activities were on the lower side while the teams were getting restructured.
Aside from that, of course, there are restructuring costs, which are also part of those results. But as I said, in an overall basis, you would see a certain portion of that operating profit situation more sustainable. As I said, a certain portion of that because we continue to invest to grow our brands as well.
Gagan Thareja — ASK Investment — Analyst
Yes, agreed. Final one from my side, which is what’s the working capital profile of your consumer business? Is it very different from the other piece? And a related one to that is ENTEROGERMINA going to be a brand within CHC — or is it housed completely outside the current SIL and therefore, will not be part of this one.
Vaibhav Karandikar — Chief Financial Officer
Yes. So working capital profile of CFC, I think both for GenMed as well as CHC working capital profile is generally good, but CHC would be slightly better. Because as I said, most of the manufacturing for CFC is localized. There is a smaller imported component. So the inventory holding for CHC is slightly better, but both businesses are cash and carry. So working capital cycle wise, both are good CFC slightly better. ENTEROGERMINA is not Sanofi India product, so it will not be a part of Sanofi Consumer Healthcare, which is the listed entity we talked about.
Gagan Thareja — ASK Investment — Analyst
Thanks for taking questions I’ll get back in the queue. Thank you.
Operator
We take our next question from the line of Ajay Sharma from Maybank. Request you to please unmute your mic and proceed with your question. Mr. Ajay Sharma, could you please accept the prompt your screen and go ahead with your questions. There’s no response from this line. We’ll move to our next question as from Mr. Nishant Sharma from Nuvama Wealth. Please unmute your microphone, Mr. Sharma please go ahead.
Ladies and gentlemen, as there is no response. With that, we now close the question-and-answer session. I now hand over the floor back to the management for closing comments.
Radhika Kartik Shah — Company Secretary and Compliance Officer
Thank you. All of you we would like to reiterate, have received our integrated annual report for FY ’22. We, today, at 3:00 pm have a 67th Annual General Meeting through audiovisual means where shareholders will get another opportunity to interact with the company, including the Board of Directors and Chairman, Mr. Aditya Narayan. Shareholders are requested to join this meeting as per the details provided in the AGM notice. Thank you all participants for attending the investor call. Thank you again.
Rodolfo Hrosz — Managing Director
Thank you very much for joining the call. Thank you for the great interactive session despite some of the issues with the mic. We have made our efforts to give you a clear answers to your questions. I hope that you can stay safe and take care. Thank you very much. Thank you for joining.
Vaibhav Karandikar — Chief Financial Officer
Thank you very much. Thank you.
Radhika Kartik Shah — Company Secretary and Compliance Officer
Thank you.
Operator
[Operator Closing Remarks]